Heated amphotericin to treat leishmaniasis

Lancet Infectious Diseases

Volumn 3, Issue 4, 2003, Pages 188-

  Bau, Pierre ^a   Bolard, Jacques ^b   Dupouy Camet, Jean ^a  

^a Assit Publique Hopitaux de Paris ^*  (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CREATININE; MILTEFOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; CELL LINE; CELL VIABILITY; CREATININE BLOOD LEVEL; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEAT TREATMENT; HUMAN; LEISHMANIA DONOVANI; LEISHMANIASIS; MAXIMUM TOLERATED DOSE; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0345505326     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00573-5     Document Type: Short Survey

References (8)

1. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2: 494-501.
2. Gaboriau F, Cheron M, Petit C, Bolard J. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother 1997; 41: 2345-51.
3. Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob Agents Chemother 1999; 43: 390-92.
4. van Etten EWM, van Vianen W, Roovers P, Frederik P. Mild heating of amphotericin B-deoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice. Antimicrob Agents Chemother 2000; 44: 1598-1603.
5. Kwong EH, Ramaswamy M, Bauer EA, Hartsel SC, Wasan KM. Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits. Antimicrob Agents Chemother 2001; 45: 2060-63.
6. Thakur CP, Dedet JP, Narain S, Pratlong F. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Trans R Soc Trop Med Hyg 2001; 95: 187-89.
7. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6: 928-34.
8. Boelaert M, Le Ray D, Van Der Stuyft P. How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis. Trop Med Int Health 2002; 7: 955-59.